Table 3.
Comorbidities and medication use.
| Hyperadrenergic Orthostatic Hypotension | Non-hyperadrenergic Orthostatic Hypotension | P-value | |
|---|---|---|---|
| Total Subjects (n) | 19 | 64 | -- |
| Comorbidities | |||
| Parkinson’s Disease | 3 (16%) | 5 (8%) | 0.376 |
| Diabetes | 2 (11%) | 3 (5%) | 0.322 |
| Multiple System Atrophy | 0 (0%) | 13 (20%) | 0.033* |
| Obstructive Sleep Apnea | 2 (11%) | 12 (19%) | 0.506 |
| Medication Usage | |||
| Opioid Analgesic Use | 3 (16%) | 4 (6%) | 0.193 |
| Benzodiazepine Use | 9 (47%) | 5 (8%) | <0.001* |
| Tricyclic Antidepressant Use | 0 (0%) | 1 (2%) | 1.000 |
| Stimulant Use | 0 (0%) | 2 (3%) | 1.000 |
| Levodopa Use | 3 (16%) | 5 (8%) | 0.376 |
| Midodrine Use | 5 (26%) | 31 (48%) | 0.116 |
| Fludrocortisone Use | 1 (5%) | 19 (30%) | 0.033* |
| Selective Serotonin Reuptake Inhibitor Use | 7 (37%) | 14 (22%) | 0.232 |
| Serotonin-Norepinephrine Reuptake Inhibitor Use | 2 (11%) | 3 (5%) | 0.322 |
| Alpha Blocker Use | 0 (0%) | 3 (5%) | 1.000 |
| Beta Blocker Use | 6 (32%) | 6 (9%) | 0.026* |
Data presented as incidence of disease or medication use in each study group. Reported P values are for Chi-square tests using Fisher’s Exact Method.
*
P-values <0.05